Literature DB >> 18813964

Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta.

John S K Kauwe1, Jun Wang, Kevin Mayo, John C Morris, Anne M Fagan, David M Holtzman, Alison M Goate.   

Abstract

The use of quantitative endophenotypes in genetic studies may provide greater power, allowing for the use of powerful statistical methods and a biological model for the effects of the disease-associated genetic variation. Cerebrospinal fluid (CSF) amyloid beta (Abeta) levels are promising endophenotypes for late-onset Alzheimer's disease (LOAD) and show correlation with LOAD status and Abeta deposition. In this study, we investigated 29 single nucleotide polymorphisms (SNPs) positive in AlzGene ( http://www.alzgene.org ) meta-analyses, for association with CSF Abeta levels in 313 individuals. This study design makes it possible to replicate reported LOAD risk alleles while contributing novel information about the mechanism by which they might affect that risk. Alleles in ACE, APOE, BDNF, DAPK1, and TF are significantly associated with CSF Abeta levels. In vitro analysis of the TF SNP showed a change in secreted Abeta consistent with the CSF phenotype and known Alzheimer's disease variants, demonstrating the utility of this approach in identifying SNPs that influence risk for disease via an Abeta-related mechanism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18813964      PMCID: PMC2726757          DOI: 10.1007/s10048-008-0150-4

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  23 in total

1.  A high-throughput gene expression analysis technique using competitive PCR and matrix-assisted laser desorption ionization time-of-flight MS.

Authors:  Chunming Ding; Charles R Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-06       Impact factor: 11.205

2.  Pedigree disequilibrium tests for multilocus haplotypes.

Authors:  Frank Dudbridge
Journal:  Genet Epidemiol       Date:  2003-09       Impact factor: 2.135

3.  Mild cognitive impairment represents early-stage Alzheimer disease.

Authors:  J C Morris; M Storandt; J P Miller; D W McKeel; J L Price; E H Rubin; L Berg
Journal:  Arch Neurol       Date:  2001-03

4.  Haplotypes extending across ACE are associated with Alzheimer's disease.

Authors:  Patrick G Kehoe; Hagit Katzov; Lars Feuk; Anna M Bennet; Boo Johansson; Björn Wiman; Ulf de Faire; Nigel J Cairns; Gordon K Wilcock; Anthony J Brookes; Kaj Blennow; Jonathan A Prince
Journal:  Hum Mol Genet       Date:  2003-04-15       Impact factor: 6.150

5.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.

Authors:  D Scheuner; C Eckman; M Jensen; X Song; M Citron; N Suzuki; T D Bird; J Hardy; M Hutton; W Kukull; E Larson; E Levy-Lahad; M Viitanen; E Peskind; P Poorkaj; G Schellenberg; R Tanzi; W Wasco; L Lannfelt; D Selkoe; S Younkin
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

6.  Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity.

Authors:  J Hu; A Igarashi; M Kamata; H Nakagawa
Journal:  J Biol Chem       Date:  2001-10-16       Impact factor: 5.157

7.  FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein.

Authors:  Lee Jae Morse; Sandra M Payton; Gregory D Cuny; Jack T Rogers
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

8.  APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.

Authors:  J A Prince; H Zetterberg; N Andreasen; J Marcusson; K Blennow
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

9.  Assessment of Alzheimer's disease case-control associations using family-based methods.

Authors:  Brit-Maren M Schjeide; Matthew B McQueen; Kristina Mullin; Jason DiVito; Meghan F Hogan; Michele Parkinson; Basavaraj Hooli; Christoph Lange; Deborah Blacker; Rudolph E Tanzi; Lars Bertram
Journal:  Neurogenetics       Date:  2008-10-02       Impact factor: 2.660

10.  Regulatory region single nucleotide polymorphisms of the apolipoprotein E gene and the rate of cognitive decline in Alzheimer's disease.

Authors:  Olivia Belbin; Janette L Dunn; Yan Ling; Linda Morgan; Sally Chappell; Helen Beaumont; Donald Warden; David A Smith; Noor Kalsheker; Kevin Morgan
Journal:  Hum Mol Genet       Date:  2007-07-05       Impact factor: 6.150

View more
  42 in total

Review 1.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

2.  The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers.

Authors:  Bruno A Benitez; Celeste M Karch; Yefei Cai; Sheng Chih Jin; Breanna Cooper; David Carrell; Sarah Bertelsen; Lori Chibnik; Julie A Schneider; David A Bennett; Anne M Fagan; David Holtzman; John C Morris; Alison M Goate; Carlos Cruchaga
Journal:  PLoS Genet       Date:  2013-08-22       Impact factor: 5.917

3.  Angiotensin-converting enzyme gene polymorphisms and risk for sporadic Alzheimer's disease: a meta-analysis.

Authors:  Xue-Bin Wang; Ning-Hua Cui; Jia-Jia Gao; Xue-Ping Qiu; Na Yang; Fang Zheng
Journal:  J Neural Transm (Vienna)       Date:  2014-05-23       Impact factor: 3.575

4.  Genetic modification of the relationship between phosphorylated tau and neurodegeneration.

Authors:  Timothy J Hohman; Mary Ellen I Koran; Tricia A Thornton-Wells
Journal:  Alzheimers Dement       Date:  2014-03-20       Impact factor: 21.566

5.  CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease.

Authors:  Jeremy Koppel; Fabien Campagne; Valérie Vingtdeux; Ute Dreses-Werringloer; Michael Ewers; Dan Rujescu; Harald Hampel; Marc L Gordon; Erica Christen; Julien Chapuis; Blaine S Greenwald; Peter Davies; Philippe Marambaud
Journal:  Mol Med       Date:  2011-05-24       Impact factor: 6.354

6.  APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Authors:  John C Morris; Catherine M Roe; Chengjie Xiong; Anne M Fagan; Alison M Goate; David M Holtzman; Mark A Mintun
Journal:  Ann Neurol       Date:  2010-01       Impact factor: 10.422

7.  Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels.

Authors:  Carlos Cruchaga; Caroline Graff; Huei-Hsin Chiang; Jun Wang; Anthony L Hinrichs; Noah Spiegel; Sarah Bertelsen; Kevin Mayo; Joanne B Norton; John C Morris; Alison Goate
Journal:  Arch Neurol       Date:  2011-01-10

8.  Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease.

Authors:  J S K Kauwe; S Bertelsen; K Mayo; C Cruchaga; R Abraham; P Hollingworth; D Harold; M J Owen; J Williams; S Lovestone; J C Morris; A M Goate
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-06-05       Impact factor: 3.568

Review 9.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

10.  Angiotensins and Alzheimer's disease: a bench to bedside overview.

Authors:  Patrick G Kehoe
Journal:  Alzheimers Res Ther       Date:  2009-07-09       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.